中信建投认为，脑机接口产业链上中游的技术进步带来下游应用端不断突破，近年来国内外在运动恢 复、语言沟通、听力重建等医疗领域的研究不断出现里程碑式成果。国家层面和各地区推出多项政策利 好行业加速发展，近期国家医保局发文为脑机接口新技术价格单独立项，其进入临床应用的服务收费路 径已经铺好。在技术革新和政策红利催化下，国内脑机接口公司有望逐步实现商业化应用。 港股异动 | 脑机接口有望逐步实现商业化应用 微创 脑科学(02172)盘中涨超13% 南京熊猫(00553)现涨 超7% 智通财经APP获悉，AH脑机接口概念早盘集体走高，截至发稿，微创脑科学(02172)涨7.34%，报14.34 港元；南京熊猫电子股份(00553)涨7.43%，报4.05港元。 消息面上，华东理工大学金晶教授科研团队发布最新研发成果"面向四足控制的混合现实增强脑-机接口 系统"，四足机器人有望执行危险搜救。此外，国家医保局此前发布《神经系统医疗服务价格项目立项 指南》，其中专门为脑机接口新技术单独立项，设立了侵入式脑机接口植入费、取出费，非侵入式脑机 接口适配费等价格项目。 ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology sector [2] Core Insights - The pharmaceutical sector continues to show strong performance, with a year-to-date return of +4.0%, outperforming the Shanghai Composite Index by 2.2% [4][11] - The report highlights the potential for recovery in consumer healthcare, driven by recent government policies aimed at boosting consumption [4][11] - Key investment themes include innovation in pharmaceuticals, turnaround opportunities, and the integration of AI technologies [4][11] Summary by Sections Market Performance - The Shanghai Composite Index rose by 1.59%, while the pharmaceutical sector increased by 1.77%, ranking 15th among 31 sub-industries [4][11] - Specific segments such as pharmaceutical commerce, traditional Chinese medicine, and medical services saw increases of 6.44%, 2.63%, and 1.46% respectively [4][11] Key Companies and Recommendations - Recommended stocks include WuXi AppTec, Aier Eye Hospital, Dong-E E-Jiao, and others, with expected earnings growth and favorable valuations [2][8] - The report emphasizes the importance of focusing on companies with improving fundamentals and low valuations, particularly in the eye care and dental sectors [5][11] Policy and Regulatory Developments - Recent government initiatives, including the introduction of child-rearing subsidies, are expected to positively impact the reproductive and maternal health sectors [6][7] - The National Healthcare Security Administration's guidelines for brain-computer interface services are anticipated to accelerate commercialization in this emerging field [6][11] Valuation Metrics - The pharmaceutical sector is currently valued at 23.4 times PE based on 2025 earnings forecasts, representing a 36.0% premium over the broader A-share market [17] - The TTM valuation stands at 27.3 times PE, which is below the historical average of 35.1 times PE, indicating potential for valuation recovery [17]

Investment Rating - The report does not explicitly state an investment rating for the industry [2] Core Insights - The pharmaceutical and biotechnology sector saw a weekly increase of 1.77%, outperforming the Wind All A index (1.49%) and the CSI 300 index (1.59%) [3][8] - Offline pharmacies and pharmaceutical distribution significantly outperformed the index with increases of 10.38% and 4.91% respectively, while in vitro diagnostics (0.77%), raw materials (0.83%), and other biological products (0.89%) lagged behind [3][9] - The report highlights the ongoing "Weight Management Year" initiative launched by the National Health Commission, emphasizing the need for continuous efforts in managing obesity and related chronic diseases [3][12] - The introduction of a pricing guide for brain-computer interface services by the National Medical Insurance Administration aims to accelerate the clinical application of new technologies [3][12] Market Weekly Review - The pharmaceutical and biotechnology sector increased by 1.77%, outperforming the Wind All A index (1.49%) and the CSI 300 index (1.59%) [3][8] - Key performers included offline pharmacies (10.38%) and pharmaceutical distribution (4.91%), while in vitro diagnostics (0.77%) and raw materials (0.83%) underperformed [3][9] - Top gainers included Kingmed Diagnostics (42.43%), Sanyou Medical (34.47%), and Dongfang Ocean (25%), while the largest declines were seen in Shuangcheng Pharmaceutical (-16.56%), Haichuang Pharmaceutical-U (-12.21%), and Ailis (-11.09%) [3][10] Industry News and Key Company Announcements - The National Health Commission's initiative on weight management aims to address obesity and its associated health risks, with a focus on chronic disease prevention [3][12] - The National Medical Insurance Administration has established pricing for brain-computer interface services, facilitating the transition of innovative technologies to clinical use [3][12] - Roche announced a collaboration with Zealand Pharma to develop a long-acting insulin analog, with a total transaction value of $5.3 billion [3][12] - Clinical trials for various drugs, including those for obesity and hypertension, have shown promising results, indicating potential market opportunities [3][14][16][18]

行业日报 | 北交所 定向可转债审批加速，助力北交所再融资常态化 证券研究报告 2025 年 03 月 13 日 北交所市场点评——20250312 核心结论 行情回顾：1）指数层面：3 月 12 日北证 50 收跌-0.6%，成交额达 420.3 亿 元，较昨日上涨 38.5 亿元。2）个股层面：当日北交所 264 家公司中 127 家 上涨，1 家平盘，136 家下跌，3 家涨停。其中涨幅前五的个股分别为：立方 控股（+30.0%）、华原股份（+30.0%）、美心翼申（+29.9%）、凯添燃气（+27.8%）、 机科股份（+23.6%），跌幅前五的个股分别为：倍益康（-8.4%）、万达轴 承（-7.5%）、西磁科技（-5.4%）、星辰科技（-5.3%）、纬达光电（-5.2%）。 相关研究 北交所：市场震荡分化，主题轮动下聚焦科技 主线与国产替代机遇—北交所市场点评—— 20250311 2025-03-12 北交所：历史新高前博弈情绪趋浓，把握政策 方向，做好中长期布局—北交所市场点评—— 20250310 2025-03-11 北交所：周内放量上涨超 6%，高波动下流动 性博弈加剧 — 北 交 所 市 ...

Core Insights - The report highlights the importance of strategic reserve and market stabilization mechanisms as emphasized by the China Securities Regulatory Commission (CSRC) [4] - The report notes a significant surge in the laser radar sector, with leading stocks experiencing over 50% growth, indicating a potential profitability breakthrough in the industry [5] - The report discusses the establishment of new companies and funds by various listed firms, indicating active corporate strategies to enhance industry collaboration and innovation [6] Domestic Financial Market - The Shanghai Composite Index closed at 3371.92, down 0.23%, while the Shenzhen Component Index closed at 10843.23, down 0.17% [2][7] - The average price-to-earnings ratios for the Shanghai Composite and ChiNext Index are 14.22 and 39.19 respectively, suggesting a suitable environment for medium to long-term investments [7] Industry Developments - The report mentions the upcoming industry conference aimed at accelerating the commercialization of solid-state batteries, with related stocks such as Linde Equipment and Yiwei Lithium Energy highlighted [5] - The humanoid robot sector is experiencing intense competition with numerous new product launches, showcasing innovation and market potential [5] Company Focus - Shanghai Electric has established an electric drive technology company in Zhejiang with a registered capital of 50 million [6] - Kaitian New Materials has set up a new fund to explore collaborative opportunities in the Hangzhou West Science and Technology Corridor [6] - Longxin Group has founded an energy technology company that includes a charging pile sales business [6]

我们不是资讯的搬运工 而是有态度的发现者 万和财富早班 2025年3月13日 | ● 国内金融市场 · | | | | · 股指期货 · | | | --- | --- | --- | --- | --- | --- | | 品种 | 收盘 | 涨跌幅 | 品种 | 收盘 | 涨跌幅 | | 上证指数 | 3371.92 | -0.23% | 上证当月连续 | 2670.00 | 0.07% | | 深证成指 | 10843.23 | -0.17% | 沪深当月连续 | 3923.20 | 0.14% | | 创业板指 | 2191.27 | -0.58% | 恒生期货指数 | 30163.53 | -1.11% | 宏观消息汇总 1。证监会:加强战略性力量储备和稳市机制建设 坚决守住风 险底线 2. 国家医保局为脑机接口医疗服务价格单独立项 3. 证监会:支持优质未盈利科技企业发行上市 二、行业最新动态 1. 激光雷达龙头美股飙涨超50%!行业迎来放量盈利曙光,相关 个股:立昂微(605358)、永新光学(603297)等 2. 行业大会将召开 固态电池产业化应用有望加速,相关个股:联 得装备(300545 ...

截至目前，公司已经拥有核心技术授权发明专利十余项，二类医疗器械注册证一张。 #核心产品介绍 此次融资由 广州同新基金、平云创科基金、深担创投、广州创投母基金、源起基金、京津冀技术创新中心以及广东协同创新控股 等多家投资机构联合投资， 资金将主要用于推动析芒医疗在脑机接口领域的技术研发与创新，特别是加速脑机接口医疗器械和关键元器件的研发工作。 除此之外，资金将用于临床试验、器械注册、市场推广及人才梯队的建设，为公司在全球脑机接口领域的竞争力提供支持。 #析芒医疗 析芒医疗成立于2022年10月，公司创始团队拥有近20年的微型医疗器械和生物芯片领域的研发经验，核心成员汇聚了包括北京大学、香港科技大学、伊利诺伊理工 大学在内的国内外顶尖学府培养的专家学者及技术人员，在微型器械、生物芯片和神经科学方面拥有深厚的学术背景和研发经验，掌握植入式神经电极和专用神经 信号处理系统等脑机接口核心技术，专注于为神经功能障碍和神经损伤患者提供前沿的医疗解决方案。 2025年1月25日， 广州析芒医疗科技有限公司（以下简称"析芒医疗"） 宣布，已完成 数千万人民币的天使轮及天使+轮融资 。 析芒医疗的核心产品分为医疗产品和科研产品两 ...

全球股市一天跌没 20 万亿元 巴菲特一笔交易赚超过 1500 亿美元 马斯克说支持特朗普不代表赞同他做的一切 关注《晚点财经》并设为星标，第一时间获取每日商业精华。 全球股市一天跌没 20 万亿元 2024 年 8 月 5 日，星期一，全球所有主要股市齐跌。根据我们的不完全统计，日本、韩国、中国、欧洲 和美国至少损失超过 20 万亿元市值。 市场其实担心衰退已好一阵子。上周五日经指数就创下 1987 年黑色星期一以来最大跌幅。信心不知何 故地在周末开始加速崩塌。巴菲特出人意料地大卖股票也许击碎了市场残存信心。现在市场恐慌，他已 备好近 2 万亿元现金储备。 周一黑色的情绪是从亚洲股市开始。日经 225 指数重挫 12.4%，韩国综合股价指数盘中熔断、收跌 8.77%。A 股和港股恒生指数不到 2% 的跌幅好于绝大多数市场。欧洲股市是在北京时间下午开盘的， 跌幅介于 2% 到 4%。 期间国际黄金一度上涨超过 1%，但随着更多在欧美市场交易的投资人加入，金价转跌。 到了北京时间晚上九点半，美股标普 500 和纳斯达克指数开盘分别跌超 4% 和 6%。其中，标普 500 指 数在开盘头 1 分钟就跌去近 1.9 ...

Temu、阿里打架，韩国电商下滑 今年一季度，韩国最大电商平台 Coupang 收入 71 亿美元，同比增长 23%，但净亏损 2400 万美元。 去年同期，它还盈利 9090 万美元。 Coupang 的亏损主要因为收购了持续亏损的奢侈品电商 Farfetch。不过剔除这一因素，它仍然在收入 增长的前提下利润下滑 —— 因为新晋中国对手的竞争。 根据第三方市调机构 Wiseapp Retail Goods 数据，Coupang 有 3000 万月活用户，是韩国第一，但速卖 通和 Temu 增长更快。今年 2 月，速卖通在当地的月活用户达到 820 万，而进入当地只有半年的 Temu、阿里打架，韩国电商下滑 索马里海盗卷土重来 特步的多品牌之路不好走 关注《晚点财经》并设为星标，第一时间获取每日商业精华。 Temu 月活达到近 580 万。到了 3 月，Temu 的月活也已经超过 800 万。 Coupang 创始人兼 CEO 金宝锡在财报电话会上说： 新的中国电商玩家提醒我们，零售业的进入门槛很低，消费者可以比其他行业更快地切换购 物选择，只需几秒钟、滑动手指即可。顾客每次购物都会投出新的一票，并且会毫不犹 ...